MedMira Strengthens and Expands Board
14 juil. 2022 19h00 HE
|
MedMira Inc.
HALIFAX, Nova Scotia, July 14, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Ms. Pascale Nini to the Board of Directors. In addition, Mr. Thomas...
MedMira Reports Third Quarter Results FY2022
29 juin 2022 22h00 HE
|
MedMira Inc.
HALIFAX, Nova Scotia, June 29, 2022 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2022. Profit and Loss Highlights ...
MedMira Receives Patent for its Unique Quantitative Diagnostic System
06 juin 2022 07h48 HE
|
MedMira Inc.
HALIFAX, Nova Scotia, June 06, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new innovative and quantitative...
MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market
27 mai 2022 08h01 HE
|
MedMira Inc.
HALIFAX, Nova Scotia, May 27, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe and any market accepting the CE mark. MedMira...
VYRA™ Product Line Update
20 mai 2022 08h52 HE
|
MedMira Inc.
HALIFAX, Nova Scotia, May 20, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRA™ product line. On the...
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test
12 mai 2022 08h40 HE
|
MedMira Inc.
HALIFAX, Nova Scotia, May 12, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark...
MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada
09 mars 2022 08h17 HE
|
MedMira Inc.
HALIFAX, Nova Scotia, March 09, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and gets clinical trials underway in Canada....
MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test
08 févr. 2022 21h00 HE
|
MedMira Inc.
HALIFAX, Nova Scotia, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) has received the CE mark for its REVEALCOVID-19® PLUS Total Antibody Test. The test will be...
MedMira Provides a Pre-Annual General Meeting Update
04 févr. 2022 07h17 HE
|
MedMira Inc.
HALIFAX, Nova Scotia, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a pre-Annual General Meeting (AGM) update on its regulatory and product development...
MedMira Reports First Quarter Results FY2022
30 déc. 2021 22h00 HE
|
MedMira Inc.
HALIFAX, Nova Scotia, Dec. 30, 2021 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2021. Profit and Loss...